newsfilter
← Latest News
GlobeNewswire·

Heron Therapeutics Announces Third Quarter 2026 Financial Results

  • Heron Therapeutics reported Q3 2026 net revenue of $35.3 million, a decrease from $38.2 million in Q3 2025.
  • ZYNRELEF® net revenue increased 13.8% to $10.6 million in Q3 2026, while APONVIE® revenue rose 49.3% to $4.5 million.
  • The Acute Care franchise generated $15.1 million in Q3 2026, up 22.5% year-over-year, with total nine-month revenue reaching $44.1 million.
  • Oncology Supportive Care revenue was $20.1 million in Q3 2026, down 22.2% year-over-year, driven by CINVANTI® sales of $20.0 million.
  • Commercial sales of SUSTOL® ceased on September 30, 2026, resulting in a 92.0% year-over-year decline in SUSTOL revenue for the quarter.
  • Heron entered a definitive agreement for CorMedix Therapeutics to acquire substantially all of Heron's assets, subject to stockholder approval.
  • Heron ended Q3 2026 with $23.4 million in cash, cash equivalents, and short-term investments.
  • The company withdrew its full-year 2026 financial guidance in August 2026 and is not providing new guidance.
  • Heron reported a net loss of $5.0 million for the three months ended September 30, 2026, compared to a $17.5 million loss in the prior year period.
  • No conference call or webcast will be held to discuss the Q3 2026 financial results.
Company
Heron Therapeutics, Inc.
Keywords
Nasdaq:HRTX, Heron Therapeutics, Inc., Heron Therapeutics